| Autor: |
Majid, Sana, McGlasson, Kathleen L, Fetterman, Jessica L, Keith, Rachel J, Weisbrod, Robert M, Palmisano, Joseph N, Breton-Romero, Rosa, Feng, Bihua, Vargees, Comreen, Bhatnagar, Aruni, Robertson, Rose M, Hamburg, Naomi M |
| Zdroj: |
Circulation (Ovid); November 2019, Vol. 140 Issue: Supplement 1 pA14816-A14816, 1p |
| Abstrakt: |
Electronic cigarettes (e-cigarettes) are increasingly used by current and former smokers. Whether e-cigarette use lowers cardiovascular (CV) risk is poorly defined. Traditional cigarettes (t-cigarettes) are known to alter lipids. Thus, we sought to investigate the impact of e-cigarettes on lipids and glucose. In the Cardiovascular Injury due to Tobacco Use (CITU) Study, we recruited healthy human participants (ages 21-45), without established CV disease and on no medications, who were either nonsmokers (N=94), sole e-cigarette smokers (N=45), dual e- and t-cigarette smokers (N=52), or t-cigarette smokers (N= 285), and measured fasting lipids and glucose. E-cigarette users were predominantly current (dual use) or former smokers, and compared to t-cigarette smokers tended to be younger, with more men and fewer black participants. As shown in the table, tobacco product users had higher glucose, TCh, TG, LDL and VLDL cholesterol, and lower HDL cholesterol levels. In multivariable regression models adjusted for age, race and sex, sole e-cigarette use remained associated with elevated TCh, TG, and LDL cholesterol levels when compared to nonsmokers (all P<0.05). Dual cigarette use was associated with lower HDL cholesterol (P<0.01). In the CITU Study, e-cigarette use produced an adverse lipid profile and glucose alterations in a pattern similar to t-cigarette use. Our findings suggest that t-cigarette smokers who concurrently use or switch to e-cigarettes may not derive notable metabolic benefits. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
